Glycologix Inc. is an emerging biotechnology company targeting locally delivered biopolymers for the protection of soft tissues. Multiple unmet medical conditions can be addressed by replenishment of naturally occurring proteoglycans. Our platform discovery engine enables the preparation of synthetic structural mimics of proteoglycans. Despite their high molecular weight, these novel materials are are highly soluble, enabling optimal tissue coverage. Focused indications for the platform include interstitial cystitis, dry eye, post-surgical adhesion prevention, osteoarthritis, spinal disk disease, and wound repair. Glycologix is supported in part by grants from the NIH.
Location: United States, Massachusetts, Beverly
Employees: 11-50
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Cortado Ve... | cortado.ve... |
Mentions in press and media 2
| Date | Title | Description |
| 04.08.2022 | Meet Mike Moradi, Venture Partner at Cortado Ventures | Oklahoma City-based Cortado Ventures invests half the fund in healthcare and life sciences Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times have changed! While there a... |
| - | Glycologix | “GlycoLogix - A ground-breaking therapy for Interstitial Cystitis / Bladder Pain Syndrome, developing biopolymers for soft tissue repair” |